Imagion Biosystems Ltd
ASX:IBX
Imagion Biosystems Ltd
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The firm's principal activities include nanotechnology, biotechnology, cancer diagnostics and medical imaging using superparamagnetic relaxometry. Its MagSense technology is a functional imaging method for detecting cancers and other critical diseases. MagSense instrument uses sensitive magnetic sensors to detect the tiny bio-safe nanoparticles. MagSense nanoparticles bound to cancer cells act like a magnetic beacon to identify the presence of a tumour. MagSense nanoparticles are supplied as an injectable solution and formulated to provide delivery to specific types of cancer cells. Its PrecisionMRX nanoparticles are developed for magnetic relaxometry and other biomedical applications. The company serves a range of applications, including detecting cancer, monitoring therapy and detecting other diseases. Its MagSense HER2 imaging agent is under phase I clinical study.
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The firm's principal activities include nanotechnology, biotechnology, cancer diagnostics and medical imaging using superparamagnetic relaxometry. Its MagSense technology is a functional imaging method for detecting cancers and other critical diseases. MagSense instrument uses sensitive magnetic sensors to detect the tiny bio-safe nanoparticles. MagSense nanoparticles bound to cancer cells act like a magnetic beacon to identify the presence of a tumour. MagSense nanoparticles are supplied as an injectable solution and formulated to provide delivery to specific types of cancer cells. Its PrecisionMRX nanoparticles are developed for magnetic relaxometry and other biomedical applications. The company serves a range of applications, including detecting cancer, monitoring therapy and detecting other diseases. Its MagSense HER2 imaging agent is under phase I clinical study.
